About this trial
Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.
Eligibility criteria
Qualifiers
High-grade T1
Any recurrent high-grade Ta
High-grade Ta & Tumor diameter greater than 3 cm or multifocal
Any CIS
Disqualifiers
Bladder cancer other than UC
MIBC or benign diseases
Incomplete tumor resection
Active infection
Trial design
Treatments tested in this trial
- Immediate postoperative chemotherapy